GETERO gemcitabine (as hydrochloride) 200 mg powder for injection vial

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

gemcitabine hydrochloride, Quantity: 228 mg

Disponible des:

Hetero Australia Pty Ltd

Designació comuna internacional (DCI):

Gemcitabine hydrochloride

formulario farmacéutico:

Injection, powder for

Composición:

Excipient Ingredients: sodium acetate trihydrate; sodium hydroxide; mannitol

Vía de administración:

Intravenous Infusion

Unidades en paquete:

1 vial

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Resumen del producto:

Visual Identification: White to off-white lyophilised powder to be reconstituted for intravenous use.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2015-03-03